Asset Management One Co. Ltd. Acquires Shares of 1,609 Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Asset Management One Co. Ltd. bought a new position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 1,609 shares of the company’s stock, valued at approximately $78,000.

A number of other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC raised its position in shares of Amphastar Pharmaceuticals by 70.0% during the 3rd quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock worth $32,000 after purchasing an additional 273 shares during the period. Innealta Capital LLC acquired a new stake in Amphastar Pharmaceuticals in the second quarter worth $55,000. Blue Trust Inc. lifted its stake in Amphastar Pharmaceuticals by 23.9% in the second quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock valued at $70,000 after buying an additional 309 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Amphastar Pharmaceuticals by 20.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company’s stock valued at $85,000 after buying an additional 301 shares during the last quarter. Finally, nVerses Capital LLC boosted its holdings in shares of Amphastar Pharmaceuticals by 37.5% during the second quarter. nVerses Capital LLC now owns 2,200 shares of the company’s stock valued at $88,000 after acquiring an additional 600 shares during the period. 65.09% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on AMPH. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Thursday, August 8th. Piper Sandler dropped their price target on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. Finally, StockNews.com cut Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $63.00.

Amphastar Pharmaceuticals Price Performance

Shares of NASDAQ AMPH opened at $48.57 on Tuesday. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $36.56 and a fifty-two week high of $65.92. The firm’s 50-day simple moving average is $48.44 and its 200 day simple moving average is $44.23. The company has a quick ratio of 2.63, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The stock has a market cap of $2.36 billion, a P/E ratio of 16.19, a P/E/G ratio of 0.93 and a beta of 0.82.

Insider Activity at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, Director Floyd F. Petersen sold 3,000 shares of the business’s stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $46.47, for a total transaction of $139,410.00. Following the sale, the director now directly owns 75,409 shares in the company, valued at approximately $3,504,256.23. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Floyd F. Petersen sold 3,000 shares of the business’s stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $46.47, for a total value of $139,410.00. Following the sale, the director now owns 75,409 shares of the company’s stock, valued at approximately $3,504,256.23. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Yakob Liawatidewi sold 5,214 shares of the company’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $52.05, for a total value of $271,388.70. Following the completion of the sale, the executive vice president now owns 74,938 shares of the company’s stock, valued at approximately $3,900,522.90. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 19,640 shares of company stock worth $990,722 in the last 90 days. Corporate insiders own 27.10% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.